Expert Opinion on Investigational Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Retatrutide: a triple incretin receptor agonist for obesity management
Expert Opin Investig Drugs. 2023 Oct 30:1-6. doi: 10.1080/13543784.2023.2276754. Online ahead of print.ABSTRACTINTRODUCTION: Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management.AREAS COVERED: Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side eff...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Avik Ray Source Type: research

Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2277389. Online ahead of print.ABSTRACTINTRODUCTION: Chronic hepatitis B infection is a major global health issue associated with significant liver-related morbidity and mortality. While existing treatments can suppress the virus effectively, they are incapable of inducing functional cure, as defined by hepatitis B surface antigen (HBsAg) seroclearance. Currently, numerous novel compounds are being developed, including bepirovirsen which is an antisense oligonucleotide (ASO).AREAS COVERED: This review summarizes the mechanism of action, pharmacokinetics, c...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Lung-Yi Mak Rex Wan-Hin Hui James Fung Wai-Kay Seto Man-Fung Yuen Source Type: research

Investigational drugs inhibiting complement for the treatment of geographic atrophy
Expert Opin Investig Drugs. 2023 Oct 30:1-8. doi: 10.1080/13543784.2023.2276759. Online ahead of print.ABSTRACTINTRODUCTION: Geographic atrophy (GA) is a progressive form of age-related macular degeneration (AMD) that leads to severe visual impairment and central vision loss. Traditional treatment options for GA are limited, highlighting the need for new therapeutic approaches. In recent years, targeting the complement system has emerged as a promising strategy for the treatment of GA.AREAS COVERED: This expert opinion article reviews the investigational drugs inhibiting the complement cascade for the treatment of GA. Spec...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Lorenzo Ferro Desideri Dmitri Artemiev Enrico Bernardi Karin Paschon Souska Zandi Martin Zinkernagel Rodrigo Anguita Source Type: research

Hepatic encephalopathy: investigational drugs in preclinical and early phase development
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2277386. Online ahead of print.ABSTRACTINTRODUCTION: Hepatic encephalopathy (HE) is a neuropsychiatric syndrome, in patients with liver disease, which affects life quality and span. Current treatments are lactulose or rifaximin, acting on gut microbiota. Treatments aiming ammonia levels reduction have been tested with little success.AREAS COVERED: Pre-clinical research shows that the process inducing HE involves sequentially: liver failure, altered microbiome, hyperammonemia, peripheral inflammation, changes in immunophenotype and extracellular vesicles an...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Tiziano Balzano Marta Llansola Yaiza M Arenas Paula Izquierdo-Altarejos Vicente Felipo Source Type: research

Investigational drugs inhibiting complement for the treatment of geographic atrophy
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2276759. Online ahead of print.ABSTRACTINTRODUCTION: Geographic atrophy (GA) is a progressive form of age-related macular degeneration (AMD) that leads to severe visual impairment and central vision loss. Traditional treatment options for GA are limited, highlighting the need for new therapeutic approaches. In recent years, targeting the complement system has emerged as a promising strategy for the treatment of GA.AREAS COVERED: This expert opinion article reviews the investigational drugs inhibiting the complement cascade for the treatment of GA. Specific...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Lorenzo Ferro Desideri Dmitri Artemiev Enrico Bernardi Karin Paschon Souska Zandi Martin Zinkernagel Rodrigo Anguita Source Type: research

Retatrutide: a triple incretin receptor agonist for obesity management
Expert Opin Investig Drugs. 2023 Oct 30. doi: 10.1080/13543784.2023.2276754. Online ahead of print.ABSTRACTINTRODUCTION: Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management.AREAS COVERED: Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side effects...
Source: Expert Opinion on Investigational Drugs - October 30, 2023 Category: Drugs & Pharmacology Authors: Avik Ray Source Type: research

Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development
Expert Opin Investig Drugs. 2023 Oct 28. doi: 10.1080/13543784.2023.2277385. Online ahead of print.ABSTRACTINTRODUCTION: Chronic urticaria (CU), including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is a prevalent, enduring, mast-cell driven condition that presents challenges in its management. There is a clear need for additional approved treatment options beyond H1 receptor antagonists and the anti-IgE monoclonal antibody (mAb), omalizumab. One of the latest therapeutic strategies targets KIT, which is considered the primary master regulator for mast cell-related disorders.AREASCOVERED: T...
Source: Expert Opinion on Investigational Drugs - October 28, 2023 Category: Drugs & Pharmacology Authors: Bettina Wedi Source Type: research